The molecular and cellular biology of lung cancer: Identifying novel therapeutic strategies

British Medical Bulletin

Volumn 95, Issue 1, 2010, Pages 47-61

  MacKinnon, Alison C ^a   Kopatz, Jens ^a   Sethi, Tariq ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

chemotherapy; genetics; inflammation; lung cancer; signal transduction; smoking

Indexed keywords

BETA1 INTEGRIN; BEVACIZUMAB; BRCA1 PROTEIN; CARBOPLATIN; CETUXIMAB; COLLAGEN TYPE 4; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBRONECTIN; GASTRIN RELEASING PEPTIDE; GEFITINIB; K RAS PROTEIN; LAMININ; MESSENGER RNA; PACLITAXEL; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRASTUZUMAB; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN;

CANCER IMMUNOLOGY; CANCER PREVENTION; CANCER RESEARCH; CANCER RESISTANCE; CANCER RISK; CANCER SCREENING; CANCER STEM CELL; CELL ADHESION; CELL CYCLE REGULATION; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DNA DAMAGE; DRUG RESEARCH; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; LUNG CANCER; LUNG CARCINOGENESIS; LUNG FIBROSIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MOLECULAR BIOLOGY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SMOKING; SYSTEMATIC REVIEW; TUMOR SUPPRESSOR GENE;

ANTICARCINOGENIC AGENTS; CARCINOMA, BRONCHOGENIC; CELL ADHESION; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION; SMOKING;

EID: 77956251901     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldq023     Document Type: Review

References (46)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003;3:733-744
3. Chang CH, Hsiao CF, Chang GC et al. Interactive effect of cigarette smoking with human 8- oxoguanine DNA N-glycosylase 1 (hOGGl) polymorphisms on the risk of lung cancer: a case-control study in Taiwan. Am J Epidemiol 2009;170:695-702.
4. Bierut LJ. Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. Trends in Pharmacol Sci 2010;31:46-51.
5. Wakelee HA, Chang ET, Gomez SL et al. Lung cancer incidence in never smokers. J Clin Oncol 2007;25:472-478
6. Tammemagi CM, Neslund-Dudas C, Simoff M et al. Smoking and lung cancer survival: the role of comorbidity and treatment. Chest 2004;125:27-37.
7. Samet JM, Avila-Tong E, Boffetta P et al. Lung cancer in never smokers: clinical epidemiology and environmental risk factors. Clin Can Res 2009;15:5626-5645
8. Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer. Curr Opin Pulm Med 2009;15:303-307
9. Yang P, Sun Z, Krowka MJ et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008;168:1097-1103
10. Kiri VA, Fabbri LM, Davis KJ et al. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med 2009;103:85-90.
11. Pontifex EK, Catherine L, Hill CL et al. Risk factors for lung cancer in patients with scleroderma: a nested case-control study. Ann Rheum Dis 2007;66:551-553
12. Moghaddam SJ, Li H, Cho SN et al. Promotion of lung carcinogenesis by chronic obstructive pulmonary disease-like airway inflammation in a K-ras-induced mouse model. Am J Respir Cell Mol Biol 2009;40:443-453
13. Nalbandian A, Yan BS, Pichugin A et al. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene 2009;28:1928-1938
14. Cook JA, Gius D, Wink DA et al. Oxidative stress, redox, and the tumor microenvironment. Semin Radiat Oncol 2004;14:259-266
15. Houghton AM, Mouded M, Shapiro SD. Common origins of lung cancer and COPD. Nat Med 2008;14:1023-1024
16. Sato M, Shames DS, Gazdar AF et al. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007;4:327-343
17. Pao W, Miller V, Zakowski M et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306-13311
18. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003;54:73-87.
19. Mok T, Wu YL. A small step towards personalised medicine for non-small cell lung cancer. Discov Med 2009;8:227-231
20. Campbell L, Blackhall F, Thatcher N. Gefitinib for the treatment of non-small-cell lung cancer. Expert Opin Pharmacother 2010;11:1343-1357
21. Tang X, Varella-Garcia M, Xavier AC et al. Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. Cancer Prev Res 2008;1:192-200.
22. Bell DW, Gore I, Okimoto RA et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 2005;37:1315-1316
23. Benedettini E, Sholl LM, Peyton M et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 2010;177:415-423
24. Aviel-Ronen S, Blackhall FH, Sheperd FA et al. K-ras mutations in non-small cell lung carcinoma: a review. Clinical Lung Cancer 2006;8:30-38
25. Wong KK. Recent developments in anti-cancer agents for the Ras/MEK/ERK pathway. Recent Pat Anticancer Drug Discov 2009;1:28-35.
26. Memmott RM, Dennis RA. The role of AKT/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. Clinical Can Res 2010;16:4-10.
27. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566
28. Rosell R, Vergnenegre A, Liu B et al. Biomarkers in lung oncology. Expert Opin Pharmacother 2010;11:1683-1693
29. Rudin CM, Salgia R, Wang X et al. Randomised phase II study of carboplatin and etoposide with or without the bcl2-antisense oligonucleotide oblimersan for extensive stage small cell lung cancer. J Clin Oncol 2008;26:870-876
30. Subramanian J, Govindan R. Molecular genetics of lung cancer in people who have never smoked. Lancet Oncol 2008;7:676-682
31. Roth JA. Gene therapy in thoracic oncology. Ann Thrac Surg 2008;85:1837-8.
32. Shimizu E, Coxon A, Otterson GA et al. RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene 1994;9:2441-2448
33. Georgiou E, Valeri R, Tzimagiorgis G et al. Aberrent p16 promoter methylation among Greek lung cancer patients and smokers: correlating with smoking. Eur J Cancer Prev 2007;16:396-402.
34. Ratschiller D, Heighway J, Gugger M et al. Overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol 2003;21:2085-2093
35. Hodkinson PS, Mackinnon A, Sethi T. Targeting growth factors in lung cancer. Chest 2008;133:1209-1216 [Review].
36. Hodkinson PS, Mackinnon AC, Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Int J Radiat Biol 2007;83:733-741
37. Ramalingam SS, Dahlberg SE, Langer CJ et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65
38. Natale RB. Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor with Vandetanib in patients with advanced or metastatic non-small cell lung cancer. J Thoracic Oncol 2008;6:28-30.
39. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. Brit J Cancer 2005;93:825-833
40. Bailey-Wilson JE, Amos CI, Pinney SM et al. A major lung cancer susceptibility locus maps to chromosome 6q23-25. Am J Hum Genet 2004;75:460-474
41. Sozzi G, Musso K, Ratcliffe C et al. Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res 1999;5:2689-2692
42. Belinsky SA, Liechty KC, Gentry FD et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-3344
43. Roth A, Harley CB, Baerlocher GM. Imetelstat (GRN163L)-telomerase-based cancer therapy. Recent Results Cancer Res 2010;184:221-234 [Review].
44. Beane J, Sebastiani P, Whitfield TH et al. A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Cancer Prev Res (Phila Pa) 2008;1:56-64.
45. Pleasance ED, Stephens PJ, OMeara S et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010;463:184-190
46. Lee W, Jiang Z, Liu J et al. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010;465:473-477.